Zobrazeno 1 - 7
of 7
pro vyhledávání: '"J Andres Suarez-Londono"'
Autor:
A Samer Al-Homsi, Frank Cirrone, Stephanie Wo, Kelli Cole, J Andres Suarez-Londono, Sharon L Gardner, Jingmei Hsu, Kelsey Stocker, Benedetto Bruno, Judith D. Goldberg, Benjamin A Levinson, Maher Abdul-Hay
Publikováno v:
Blood Advances.
Reducing the incidence of graft-versus host disease (GvHD) following haploidentical hematopoietic stem cell transplantation (HSCT) is warranted. Post-transplant cyclophosphamide (PTCy) is the main agent used for GvHD prevention in this setting. It re
Autor:
A Samer Al-Homsi, Frank Cirrone, Kelli Cole, J Andres-Suarez Londono, Sharon Gardner, Jingmei Hsu, Stephanie Wo, Kelsey Stocker, Judith Goldberg, Benjamin Levinson, Maher Abdul-Hay
Publikováno v:
Transplantation and Cellular Therapy. 29:S249-S250
Autor:
Frank Cirrone, Niti Patel, Maher Abdul Hay, J Andres-Suarez Londono, Benedetto Bruno, Sarah G Leone, Kelli Cole, A Samer Al-Homsi
Publikováno v:
Transplantation and Cellular Therapy. 28:S462-S463
Autor:
A Samer Al-Homsi, Frank Cirrone, Kelli Cole, Kelsey Stocker, Benedetto Bruno, J Andres-Suarez Londono, Judith Goldberg, Maher Abdul Hay
Publikováno v:
Transplantation and Cellular Therapy. 28:S305
Autor:
Sarah G Leone, Sunil Rohatgi, Frank Cirrone, J Andres-Suarez Londono, Maher Abdul Hay, Benedetto Bruno, Kelli Cole, Ahmad Samer Al-Homsi
Publikováno v:
Transplantation and Cellular Therapy. 28:S142
Autor:
Maher Abdul-Hay, Tsivia Hochman, Judith D. Goldberg, Benedetto Bruno, A. Samer Al-Homsi, Kelsey Stocker, Frank Cirrone, J Andres Suarez-Londono, Kelli Cole
Publikováno v:
Blood. 138:3892-3892
Introduction. Prevention of graft-versus-host disease (GvHD) following allogeneic hematopoietic cell transplantation (AHCT) remains a major challenge. The combination of methotrexate (MTX) and a calcineurin inhibitor has been the standard regimen for
Autor:
Kelsey Stocker, Maher Abdul-Hay, Kelli Cole, Frank Cirrone, A. Samer Al-Homsi, J Andres Suarez-Londono, Benedetto Bruno, Judith D. Goldberg
Publikováno v:
Blood. 138:3906-3906
The introduction of post-transplant cyclophosphamide (PTCy) has circumvented the need for T-cell depletion following haploidentical stem cell transplantation (SCT). By expanding the donor pool for patients from certain ethnic minorities, this has add